
The recommendation is backed by data from the phase 3 LITESPARK-011 trial.
Eric Jonasch, MD, professor, Department of Genitourinary Medical Oncology, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, offers his advice for physicians treating patients with renal cell carcinoma.